Spyre Therapeutics, Inc. (SYRE) News
Track canonical SquawkNews coverage tagged to SYRE, Spyre Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 27 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SYRE: Global trials of optimized biologic combinations in autoimmune diseases set up multiple late-stage catalysts
Focused on advancing optimized biologic combinations for autoimmune diseases, the company is running a global, near-phase III scale trial in IBD, with monotherapy and combination arms. Long-acting antibodies show efficac
EQUITY | Sep 10, 2026, 01:45 PM UTC
L
SYRE: Combination antibody therapies in autoimmune diseases advance toward pivotal global trials
Focused on advancing combination antibody therapies for autoimmune diseases, the pipeline targets IBD, rheumatology, and dermatology, with global trials and a strong financial position. Key readouts this year and next wi
EQUITY | Sep 10, 2026, 01:08 PM UTC
L
SYRE: Advancing innovative antibody combinations for autoimmune diseases with pivotal data expected in 2027
The company is advancing best-in-class antibody therapies for autoimmune diseases, with a focus on IBD and expansion into rheumatic and dermatologic indications. Strong recent data, a robust financial position, and a dif
EQUITY | Sep 09, 2026, 03:50 PM UTC
L
SYRE climbs on progress in long-acting autoimmune antibody programs
SYRE is highlighted for significant progress in long-acting antibody therapies for autoimmune diseases, including IBD and expansion into rheumatic and dermatologic indications, with combination strategies supported by re
EQUITY | Sep 09, 2026, 02:54 PM UTC
L
Spyre Therapeutics price target kept at $123 by Wedbush
Wedbush maintained its $123.00/share price target for Spyre Therapeutics.
EQUITY | Sep 09, 2026, 12:26 PM UTC
L
BTIG maintains $121 price target on Syre Therapeutics
BTIG maintained a $121.00/share price target for Syre Therapeutics, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 03:32 PM UTC
M
Spyre says SPY003 shows statistically significant RHI reduction at Week 12
Spyre’s SPY003 (anti-IL-23) met its primary endpoint with a statistically significant 10.0-point reduction in Robart’s Histopathology Index score versus baseline at Week 12 (p<0.0001).
EQUITY | Sep 08, 2026, 12:08 PM UTC
M
Spyre says Phase 2 SKYLINE Part A met primary endpoint
Spyre said SPY003 met the primary endpoint in Phase 2 SKYLINE Part A, with a 10.0-point RHI reduction at Week 12 and supportive remission and endoscopic improvements. Part B is enrolling, with topline in 2027.
REGULATION | Sep 08, 2026, 12:03 PM UTC
L
Spyre Therapeutics announces inducement awards grants
Spyre Therapeutics said it has announced grants of inducement awards, per a Globe Newswire release dated Sept. 04, 2026.
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
SYRE - Spyre Therapeutics Announces Grants of Inducement Awards
SYRE - Spyre Therapeutics Announces Grants of Inducement Awards
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
Spyre Therapeutics to participate in upcoming September investor conferences
Spyre Therapeutics (NASDAQ:SYRE) says it will participate in upcoming September investor conferences, according to a Globe Newswire update from Waltham, Massachusetts.
EQUITY | Sep 03, 2026, 08:07 PM UTC
L
SYRE - Spyre Therapeutics to Participate in Upcoming September Investor Conferences
SYRE - Spyre Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 03, 2026, 08:06 PM UTC
L
Deutsche Bank keeps Spyre Therapeutics at Buy
Deutsche Bank maintains a Buy rating on Spyre Therapeutics.
EQUITY | Aug 26, 2026, 06:11 PM UTC
L
Spyre Therapeutics Is Maintained at Outperform by Wedbush
Spyre Therapeutics Is Maintained at Outperform by Wedbush
EQUITY | Aug 26, 2026, 12:48 PM UTC
L
Spyre Therapeutics reports SKYWAY RA sub-study topline results for SPY072
Spyre Therapeutics announces topline results from the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial of SPY072.
EQUITY | Aug 25, 2026, 08:01 PM UTC
L
SYRE - Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SYRE - Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 04, 2026, 08:02 PM UTC
L
Spyre Therapeutics just downgraded at Wolfe Research, here's why
Spyre Therapeutics just downgraded at Wolfe Research, here's why
EQUITY | Jul 28, 2026, 12:26 PM UTC
L
SYRE downgraded from Outperform to Peer Perform @ Wolfe
SYRE downgraded from Outperform to Peer Perform @ Wolfe
EQUITY | Jul 28, 2026, 12:25 PM UTC
L
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD Cowen LAUR: UNDERWEIGHT @ MS LEVI: EQUAL WEIGHT @ WFC MPLT: EQUAL WEIGHT @ MS P
EQUITY | Jul 28, 2026, 11:11 AM UTC
M
SYRE Drops 12%
Spyre Therapeutics stock plunges over 12% on Wednesday due to large insider stock sales
EQUITY | Jun 24, 2026, 03:56 PM UTC
H
HTZ: -21% on Notes Offering
Hertz Global Holdings is down 21% premarket on a proposed offering of $300 million of exchangeable senior first-lien secured PIK notes and $100 million of common stock
EQUITY | Jun 24, 2026, 01:13 PM UTC
H
HTZ: -17% on Notes Offering
Hertz Global Holdings is down 17% premarket on a proposed offering of $300 million of exchangeable senior first-lien secured PIK notes and $100 million of common stock
EQUITY | Jun 24, 2026, 12:22 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC
H
SAGT Surges 76%
Sagtec Global shares rise 75.6% in pre-market trading after issuing financial year 2026 guidance projecting 35% revenue growth
EQUITY | Jun 22, 2026, 09:23 AM UTC